April 12, 2021
Patients with STEMI undergoing PCI who received an intravenous dose of tocilizumab, an inhibitor of the inflammatory cytokine interkleukin-6 (IL-6), prior to their procedure appeared to have less myocardium irreversibly damaged when compared with patients who received matching placebo, according to a small, proof-of-concept study.
While there was no significant difference in the final infarct size at 6 months, the adjusted myocardial salvage index, which accounts for the extent to which ischemic myocardium recovers after reperfusion and was the trial’s primary endpoint was significantly higher among patients treated with tocilizumab. As for the clinical significance of the improvement with the IL-6 inhibitor, lead investigator Kaspar Broch, MD, PhD (Oslo University Hospital Rikshospitalet, Norway), told TCTMD that’s yet to be shown.
Running on Borrowed Life
somatosphere.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from somatosphere.net Daily Mail and Mail on Sunday newspapers.
CNIC researchers explain how high blood pressure, the most important cause of disease worldwide, acc
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.